BPC+PEA 500

The peptide BPC-157 is a pentadecapeptide made up of 15 amino acids that is derived from human gastric juice. It has a molecular weight of 2212 daltons and its sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. BPC-157 is also known as the “Wolverine” peptide, for its ability to help support repair and recovery, many have also found that it’s helped support gut issues, gastric reflux, depression, performance, and more.

BPC-157 has been studied for a variety of topics and has shown to be helpful in many areas such as: tendinopathy, gastric ulcers, general inflammation, and even neuroprotection. BPC-157 seems to work by interacting with our cells’ systems that are responsible for growth and repair, thus helping the body to heal itself.

One of the most exciting potential benefits of BPC-157 is its ability to help with tendon repair. Tendons are the tough, fibrous tissues that connect our muscles to our bones and are essential for movement. However, tendons are also susceptible to injury and can often be slow to heal. This is where BPC-157 comes in; by aiding in the repair and regeneration of damaged tendons, BPC-157 could potentially help reduce recovery time and improve outcomes following an injury.

BPC-157 has also been shown to be beneficial in supporting the healing of gastric ulcers. Gastric ulcers are a type of peptic ulcer that develops in the lining of the stomach. They are a common and often painful condition that can be difficult to treat. However, BPC-157 has been shown to promote healing of gastric ulcers and improve symptoms.

There is also some evidence to suggest that BPC-157 may be helpful in supporting inflammatory bowel disease (IBD). IBD is a chronic condition that causes inflammation of the digestive tract. Symptoms can include abdominal pain, diarrhea, and weight loss. BPC-157 has been shown to reduce inflammation and improve symptoms in animal models of IBD. Overall, BPC-157 appears to be a promising compound with the potential to support a variety of gastrointestinal disorders.

One of the best things about BPC-157 is that it is orally bioavailable, particularly the arginate salt we use, is extremely stable.   We wanted to make sure that oral bioavailability was maximized which is why we included a molecule called SNAC in our formulation.

Salcaprozate sodium, or SNAC, is one of the most advanced intestinal permeation enhancers that have been tested in clinical trials for oral delivery of macromolecules. It was originally designed for the oral delivery of insulin. In one study, SNAC increased the absorption of a peptide (a short chain of amino acids) by nine-fold without affecting tight junctions.

Healthgevity’s formulation includes an optimal ratio of salcaprozate sodium to our active ingredients. This combination results in exceptional oral absorption of this combination without compromising its stability or efficacy.

Palmitoylethanolamide (PEA) is an 18-carbon long- chain fatty acid. Nobel Prize winner Levi-Montalcini identified PEA as a naturally occurring molecule, describing its value in treating chronic infections and pains. Following her discovery, hundreds of scientific studies have been published to show that it is very effective and safe to use. PEA is thought to work by supporting the inflammatory response through the PPAR-a receptor, COX-2 and through effects on NF-kappaB signaling while also by restoring balance in the endocannabinoid system. Its mechanism of action is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs).

Palmitoylethanolamide (PEA) is the body’s go-to- molecule and is made on demand when required under disease conditions. Due to its ubiquitous nature and presence in all cells, PEA has wide-ranging therapeutic applications. Some of the most common clinical applications are analgesic effects, chronic pain, and inflammation support.

PEA has anti-inflammatory effects on the body by inhibiting the production of pro-inflammatory cytokines and by reducing the activity of activated microglia cells. It is also thought to reduce pain by modulating the neurotransmitters involved in pain signaling. In addition to its analgesic and anti-inflammatory effects, PEA is also thought to offer neuroprotection by reducing the levels of reactive oxygen species and by modulating cell death pathways. It has also been shown to improve cognitive function in animal models of Alzheimer’s disease.

The endocannabinoid system is involved in a wide range of physiological processes, including digestion. The role of the endocannabinoid system in the gut has been studied extensively and it is now well-established that cannabinoids modulate gastrointestinal motility, secretion and inflammation. PEA is one of the most abundant endocannabinoids in the gut and is thought to play a key role in gut-brain axis. The endocannabinoid system is known to be involved in various digestive disorders, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastroesophageal reflux disease (GERD).

Several studies have shown that PEA is effective in reducing symptoms of IBS, such as abdominal pain and bloating. A recent clinical trial showed that a PEA-based product was able to significantly reduce IBS symptoms in patients who did not respond to standard therapy. PEA has also been shown to be effective in supporting other digestive disorders such as GERD and IBD. In a clinical trial, PEA was able to significantly reduce symptoms of GERD, such as heartburn and acid reflux.